Kornimate/medical-research-clean huggingface dataset:
a study evaluating the effects of filgotinib in children and teenagers with ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the aim of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (pk) of filgotinib as a treatment for uc in children and adolescents aged from 8 to less than 18 years. approximately 80 subjects from 8 to \<18 years of age with moderately to severely active uc, including a minimum of 8 subjects from 8 to \<12 years of age, will be enrolled in this study. during the study, eligible subjects will take the investigational product (ip) on-site at week 4, week 10, and week 22 (in the morning; with or without food). on all other days, subjects will take ip at home (in the morning; with or without food). subjects who do not achieve mmcs remission and/or mcs response at week 10 will continue with induction treatment until week 22. subjects who do not achieve pucai remission at week 22 will be permanently discontinued from the study. subjects will all receive a filgotinib dose targeting the same systemic exposure as that observed in adults with uc treated with 200 mg q.d.


Eligibility criteria:
inclusion criteria: * subject must have a minimum body weight (bw) of 15 kg. * subject: * has documented diagnosis of uc with a minimum duration of 3 months, * has mmcs of 5 to 9, and an mcs endoscopic score \>=2, rectal bleeding \>=1, and stool frequency \>=1, * has had an inadequate response, loss of response, intolerance, or has medical contraindications to corticosteroids, immunosuppressants, and/or biologic therapy. this includes subjects who depend on corticosteroids to control their symptoms and who experience worsening of their disease when attempting to wean off corticosteroids. exclusion criteria: * subject has a diagnosis of inflammatory bowel disease -unclassified or indeterminate colitis, isolated proctitis, or toxic megacolon. * subject has an active infection. * subject with a history of complicated herpes zoster infection (with multi-dermatomal, disseminated, ophthalmic, or central nervous system involvement). * currently on any therapy for chronic infection (such as pneumocystis, cytomegalovirus, herpes simplex, herpes zoster, or atypical mycobacteria). * subject has a history of colectomy or extensive small bowel resection. * subject with psychological or cognitive difficulties that might interfere with study participation. * subject has any previous exposure to a janus kinase inhibitor or medication with a similar mode of action (e.g. tofacitinib, baricitinib, upadacitinib). * female subject is pregnant or breast feeding or intending to become pregnant or breastfeed during the study.
impact of photodynamic therapy as an adjunct to non-surgical periodontal treatment on clinical and biochemical parameters among patients having mild rheumatoid arthritis with periodontitis

Conditions: Rheumatoid Arthritis; Chronic Periodontitis

Summary: purpose: to evaluate the efficacy of photodynamic therapy (pdt) as an adjunct to non-surgical periodontal therapy on the clinical periodontal and biochemical parameters among patients with rheumatoid arthritis (ra) having periodontitis. methods: a total of 50 ra patients with periodontitis were included. the subjects were equally divided into two groups: group a - scaling and root planning (srp) + pdt; group b - srp only, respectively. plaque score (ps), bleeding on probing (bop), pocket depth (pd) and clinical attachment level (cal) were estimated. the biochemical parameters included the assessment of interleukin 6 (il-6), tumor necrosis factor-alpha (tnf-α) and rheumatoid factors (rfs). multiple comparisons were established by employing the bonferroni's post-hoc test for both clinical and laboratory biomarker data. the mann-whitney test was used to compute the p-value for intergroup comparisons. for intra-group comparisons, the p-value was computed with the help of wilcoxon signed ranks test.


Eligibility criteria:
inclusion criteria: * patients aged ≥25 years * satisfying the 2010 acr/eular categorization criteria (with active ra with ≥6 joint involvement and under anti-ra medication ≥3 months) * patients having \>20 teeth diagnosed with generalized (\>30% of sites) chronic periodontitis with pd ≥ 4mm and/or cal ≥ 4mm and vertical bone loss of at least 4 mm on radiography. exclusion criteria: * patients who had underwent periodontal therapy or antimicrobial therapy in the last 6 months * any joint replacement * pregnancy/lactating mothers * patients having other forms of systemic diseases such as diabetes mellitus, hypertension or acquired immunodeficiency syndrome (aids)

Keywords: photodynamic therapy biomarkers inflammation rheumatoid arthritis chronic periodontitis
end-expiratory transpulmonary pressure-guided vs electrical impedance tomography-guided peep titration methods in patients with intra-abdominal hypertension combined with acute respiratory distress syndrome: a randomized crossover controlled study

Conditions: Intra-abdominal Hypertension; Acute Respiratory Distress Syndrome (ARDS)

Summary: this study aims to adopt a randomized crossover design to compare the effects of end-expiratory transpulmonary pressure-guided peep titration and eit-guided peep titration on local lung ventilation, shunt, dead space, and ventilation-perfusion (v/q) ratio as monitored by eit. additionally, it will evaluate their impact on respiratory mechanics, chest wall mechanics, mechanical power, hemodynamics, gas exchange, intra-abdominal pressure, abdominal perfusion pressure, and renal perfusion. by identifying an optimal peep titration strategy for patients with intra-abdominal hypertension (iah) and acute respiratory distress syndrome (ards), this study aims to develop a mechanical ventilation approach that maintains lung recruitment and minimizes lung injury while avoiding adverse effects on other organs. the findings could facilitate the clinical application of this strategy and benefit a broader population of patients with iah and ards.


Eligibility criteria:
inclusion criteria: 1. age: 18-80 years; 2. meets iah ≥12 mmhg; 3. meets the diagnostic criteria of the new global definition of ards in the 2023 edition; 4. pao2/fio2 ≤ 150; 5. within 36 hours of invasive mechanical ventilation; 6. patients or their family members were consulted, agreed to participate in the trial, and signed an informed consent form. exclusion criteria: 1. age \ 80 years; 2. uncorrected shock of any type; 3. chronic obstructive pulmonary disease, interstitial lung disease, pulmonary embolism, right heart failure, pulmonary hypertension, or severe cardiac arrhythmia; 4. pneumothorax or bronchopleural fistula or lobectomy or other surgery of the lungs within 2 weeks of surgery; 5. non-invasive ventilation or transnasal high-flow oxygen; 6. with relevant contraindications to the application of eit (large chest skin injuries, infections, pacemaker implanters, in vivo automatic defibrillator implantation, etc.) pneumothorax, mediastinal emphysema, massive pleural effusion; 7. oesophageal obstruction, oesophageal perforation, severe oesophageal variceal bleeding, upper gastrointestinal surgery, and other factors that make it impossible to place an oesophageal pressure catheter; 8. diaphragmatic hernia, thoracic deformity; patients with obvious pulmonary hernias; 9. prolongation of prothrombin time (pt), activated partial thromboplastin time (aptt) to two times the high limit of normal values or with active bleeding in the nasopharynx; 10. severe neurological disease: intracranial hypertension or neuromuscular disease, etc; 11. pregnant and lactating women; 12. patients to be treated with ecmo; 13. re-admission to the icu of patients who have already been included in this study, or who are participating in other clinical studies;
maternal iron deficiency and/or iron deficiency anemia to neonatal hemoglobin concentration and iron stores

Conditions: Relation, Mother-Child

Summary: study the relationship between maternal iron deficiency (id) and/or iron deficiency anemia (ida) to neonatal hemoglobin concentration and iron stores at birth

iron deficiency is a common micronutrient deficiency in pregnant women specially in developing countries as increasing demands on maternal iron stores as consequences of expansion of maternal red blood cell mass and the requirement of the developing fetus. the relationship between maternal iron stores and fetal iron extraction has received considerable attention as iron deficiency places neonates at high risks for cognitive, motor, social-emotional, and neurodevelopmental problem. moreover, requirement of iron is high for rapid growth and differentiation of the fetus and thus a well-balanced iron hemostasis is required. this balance can be threatened in neonates born to iron compromised mothers. some studies have suggested that the fetus reflects maternal iron stores, but this concept is still being debated as few other studies show contrasting results, majority of studies have been done in developed countries. to draw the consensus regarding the result, more studies needed to clarify the effect of maternal iron status on fetal stores are required. proper understanding of the relationship between maternal and neonatal iron indices will help in formulating protocols that is required to improve the maternal and neonatal outcomes, so investigating the effect maternal iron on fetal iron indices can be of great value, so that early intervention to prevent or reverse the adverse effect of iron deficiency on development issues much before iron deficiency becomes sever can be instituted.

Eligibility criteria:
inclusion criteria: * all pregnant women and their infant pairs who have given consent to participate. * mothers age: 21-40 years' old. * term infants (37-42 weeks of gestation) with birth weight ≥2500 g born to mothers who had an uncomplicated normal singleton vaginal delivery or caesarian section delivery was included. exclusion criteria: * mothers with a history of antepartum hemorrhage, pre-mature labor pain, high-risk pregnancy (eg. history of trauma and severe infection during pregnancy), severe hyperemesis, pre-eclampsia severe anemia requiring blood transfusion, and any chronic medical illnesses as: gestational diabetes, hypertension, hypothyroidism, epilepsy, liver disease, renal disease cardiorespiratory disease, immunodeficiency syndrome, and hematological (other causes of anemia) * infants who suspected with congenital and/or chromosomal anomalies and pathological jaundice, also multiple pregnancy was excluded from the study. * mothers withdrew from given a written consent will be excluded from the study.

Keywords: anemia iron deficiency iron stores
perio. maint. with diode lbr

Conditions: Chronic Periodontitis

Summary: the primary aim of this pilot study is to determine whether the test methods described feasibly achieve the goal defined for a future clinical study. the purpose is a quantitative assessment of the bactericidal effect of two adjunctive treatments compared to that of conventional periodontal maintenance debridement. patients who meet eligibility criteria and are enrolled in the study will receive the standard of care, whole mouth periodontal maintenance treatment using ultrasonic scalers to debride deposits within the gingival sulcus. subsequently, each of three of the quadrants will be randomly assigned to a test group (keeping the fourth quadrant as the control), thus, a "split-mouth" study design. microbial samples will be collected using sterile paper points inserted into each tooth site involved in the study at baseline (s1) before test treatment and one week after test treatment (s2). samples will be analyzed with real time qpcr to identify and quantify specific periodontal pathogens. data analysis will compare the post-treatment results to baseline, the control treatment arm to the test treatment arm, and the test treatments among each other.


Eligibility criteria:
inclusion criteria: * • adults, over 30 years old * at least one site in each quadrant having cal 4-6mm and/or ppd 5-7mm (at least 4 sites per patient) with all adjacent sites having ppd\<5mm * patients who received srp treatment in the past 12 months, who are returning for routine periodontal maintenance debridement, whose pockets are stable at ppd 5-7mm (not showing improvement or decline) exclusion criteria: * • patients who have had periodontal surgery within 12 months * a site adjacent to the potential study site having either an implant placed or a ppd\>7mm * patients taking systemic antibiotics or immunosuppressants during or within 3 months of the study * chronic smokers or smokeless tobacco users
mckenzie vs manual therapy for low back pain

Conditions: Low Back Pain

Summary: a comparative study evaluating the effectiveness of the mckenzie technique versus manual therapy in patients with nonspecific low back pain. the study aims to assess which intervention is more effective in reducing pain and improving functional mobility.

the study compares mckenzie method, a directional preference-based approach involving repeated movements and posture correction, against manual therapy, which includes hands-on techniques such as mobilizations and manipulations. patients with nonspecific low back pain will be randomly assigned to one of the two groups and treated over a defined period. outcomes will be measured using pain and disability scores.

Eligibility criteria:
inclusion criteria: * diagnosis of nonspecific low back pain lasting more than 4 weeks * willing to participate and comply with the study protocol exclusion criteria: * history of lumbar spine surgery * presence of spinal fracture, tumor, or infection * pregnant women * severe osteoporosis or spinal deformity

Keywords: low back pain
complete removal of neoplastic large colorectal polyps: a prospective randomized comparison of endoscopic mucosal resection or conventional polypectomy

Conditions: Colorectal Polyps

Summary: recently, it was reported that the incomplete resection rate of neoplastic large polyps after conventional polypectomy was markedly high in clinical practice. the incomplete resection rate of neoplastic large polyps after endoscopic mucosal resection (emr) is not known. the aim of this study is to compare the incomplete resection rate of neoplastic large polyps after emr or conventional polypectomy. the emr technique is preferable to conventional polypectomy for the complete resection of the large polyps (\>15 mm in diameter)


Eligibility criteria:
inclusion criteria: * inclusion criteria were nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter. exclusion criteria: * less than 20 years old, history of previous colorectal surgical resection, american society of anesthesiologists class iii and iv, allergic to propofol used or its components (soybeans or eggs), or poor bowel preparation.

Keywords: nonpedunculated neoplastic colorectal polyps
virtual reality walking for neuropathic pain in spinal cord injury

Conditions: Spinal Cord Injuries; Neuropathic Pain

Summary: this study will examine the effectiveness of one of two virtual reality treatments on neuropathic pain in individuals with spinal cord injury.

the investigators are investigating the effectiveness of one of two possible investigational virtual reality treatments on neuropathic pain in individuals with spinal cord injury. participants will be randomized to one of these two treatments.

Eligibility criteria:
inclusion criteria: * individuals with complete paraplegic spinal cord injury who report chronic neuropathic pain * individuals with persistent spinal cord injury neuropathic pain * more than one - year post injury * stable medication regimen for the past month exclusion criteria: * conditions that impair movement of the arms * significant cognitive impairment as suggested by apparent incomprehension of screening questions as judged by the evaluator * for those for whom voluntary arm movement would cause sufficient discomfort (\>4/10) that could prevent trial completion will be excluded from participation

Keywords: virtual reality
effect of ferric carboxymaltose on exercise capacity and cardiac function in patients with iron deficiency and chronic heart failure

Conditions: Chronic Heart Failure; Iron Deficiency; Iron Deficiency Anemia; Anaemia

Summary: this study is designed to assess, relative to placebo, the effects on the evolution of exercise capacity and symptomatic status of the addition of iron treatment with fcm (ferric carboxymaltose) to the basic regimen of ambulatory patients with stable symptomatic chronic chf (congestive heart failure) and iron deficiency.


Eligibility criteria:
inclusion criteria: * in new york heart association (nyha) ii-iii functional class due to stable symptomatic chronic heart failure (chf) * left ventricular ejection fraction (lvef) 40% or lower for patients in nyha ii and 45% or lower in nyha iii * screening haemoglobin (hb) at least 9.5 g/dl but below or equal to 13.5 g/dl (average of 2 haemoglobin concentrations) * screening ferritin below 100 µg/l, or below 300 µg/l when transferrin saturation (tsat) is below 20% exclusion criteria: * history of acquired iron overload. * known active infection, clinically significant bleeding, active malignancy. * chronic liver disease and/or screening alanine transaminase (alt) or aspartate transaminase (ast) * anaemia due to reasons other than iron deficiency * immunosuppressive therapy or renal dialysis (current or planned within the next 6 months). * history of erythropoietin, i.v. or oral iron therapy, and blood transfusion in previous 12 weeks and/or such therapy planned within the next 6 months. * unstable angina pectoris as judged by the investigator, clinically significant uncorrected valvular disease or left ventricular outflow obstruction, obstructive cardiomyopathy, poorly controlled fast atrial fibrillation or flutter, poorly controlled symptomatic brady- or tachyarrhythmias. * acute myocardial infarction or acute coronary syndrome, transient ischaemic attack or stroke within the last 3 months. * coronary-artery bypass graft, percutaneous intervention (e.g. cardiac, cerebrovascular, aortic; diagnostic catheters are allowed) or major surgery, including thoracic and cardiac surgery, within the last 3 months.

Keywords: chronic heart failure iron deficiency iron deficiency anaemia anaemia heart disease
a study to evaluate the safety and tolerability of sage-718 in participants with parkinson's disease mild cognitive impairment (pd-mci)

Conditions: Parkinson Disease; Cognitive Dysfunction

Summary: the primary purpose of this two-part study was to evaluate the safety and tolerability of sage-718 and its effects on cognitive, neuropsychiatric, and motor symptoms in participants with parkinson's disease mild cognitive impairment (pd-mci).


Eligibility criteria:
inclusion criteria: 1. meet the following criteria for pd-mci: have a confirmed diagnosis of idiopathic pd according to 2015 movement disorder society (mds) clinical diagnostic criteria; meet mds task force criteria for mci in pd. 2. have a score of 20 to 25 (inclusive) on the montreal cognitive assessment (moca) at screening. 3. meet criteria for hoehn \& yahr stage i to iii (mild to moderate motor severity) at screening. 4. have stable motor symptoms for at least 4 weeks prior to screening, in the opinion of the investigator. exclusion criteria: 1. have a diagnosis of dementia of any etiology, including but not limited to: dementia associated with pd (probable or possible), dementia with lewy bodies, alzheimer's dementia, and vascular dementia. 2. have any indication of parkinsonism other than idiopathic pd. 3. in the opinion of the investigator, be experiencing unpredictable fluctuations in motor and/or nonmotor symptoms associated with pd. 4. have an ongoing central nervous system condition other than idiopathic pd, including active neurologic and/or nonremitted psychiatric disorders, in the opinion of the investigator. 5. have a history of brain surgery, deep brain stimulation, a significant head injury causing loss of consciousness greater than 30 minutes, or hospitalization due to a brain injury. 6. have experienced significant psychotic symptoms within the past 3 months, including those associated with pd medications, as determined by the investigator.

Keywords: parkinson's disease cognitive dysfunction sage-718
description des troubles respiratoires chez les patients suivis pour une sclérose en plaques (sep) sévère

Conditions: Multiple Sclerosis; Respiration Disorders

Summary: the purpose of this study is to describe respiratory disorders in patients with severe multiple sclerosis (edss from 6.5).


Eligibility criteria:
inclusion criteria: * diagnosis criteria of multiple sclerosis (ms) fulfilling revised mcdonald criteria (2010) * edss score from 6.5 * no relapse during the 3 last months * informed consent prior to any study procedure exclusion criteria: * any severe chronic obstructive pulmonary disease (iii or iv) * pregnancy or woman with childbearing potential * contraindication to mri
myoring versus keraring implantation for keratoconus

Conditions: Keratoconus

Summary: various approaches, including surgical and non-surgical management have been proposed for keratoconus. one of the surgical procedures is intrastromal corneal ring implantations that have been designed to achieve refractive readjustment by flattening the cornea. there are different models of intrastromal corneal rings available: intrastromal corneal ring segments (icrs) such as keraring and intrastromal corneal continuous ring (iccr) like myoring. most studies of these two types of ring implantation outcomes are retrospective case series. thus, this randomized clinical trial study was designed with the aim of comparing visual and refractive outcomes and complications of insertion myoring versus keraring using femtosecond laser. keratoconus patients with compound myopic astigmatism who meet the inclusion criteria will randomly allocated to the keraring and myoring groups. subsequently, the clinical outcomes of two groups will be compared at one,3 and 6 months after surgery.


Eligibility criteria:
inclusion criteria: * keratoconus patients and : * age between 20 to 40 * corneal thickness\> 380 microns * mean keratometry between 44 to 60 d * clear central cornea * patients should be discontinued their contact lenses for 3 weeks prior to the exams * contact lenses in tolerance * 20/200\<visual acuity \<20/30 exclusion criteria: * positive pregnancy test * breast-feeding * history of glaucoma, cataract, vernal and atopic keratoconjunctivitis * history of previous ophthalmologic surgery, keratorefractive surgery on the operative eye * dry eye * corneal stromal disorders * history of herpetic keratitis * pellucid marginal degeneration * corneal grafts * retinal disorders * nystagmus and uncooperative disposition * neuro-ophthalmologic disorders * intraocular pressure \ 21 mmhg * patients with autoimmune, connective tissue disorders, diabetes and immunosuppressive drugs users * hyperopia
a study of jnj-77242113 in participants with moderately to severely active ulcerative colitis

Conditions: Colitis, Ulcerative

Summary: the purpose of this study is to evaluate the safety and effectiveness of jnj-77242113 compared with placebo in participants with moderately to severely active ulcerative colitis.


Eligibility criteria:
inclusion criteria: * signed informed consent form 18 years of age or older * documented diagnosis of ulcerative colitis (uc) of at least 12 weeks prior to screening * moderately to severely active uc as per the modified mayo score * demonstrated inadequate response to or intolerance of conventional therapy and/or advanced therapy as defined in the protocol exclusion criteria: * participants with current or prior diagnosis of fulminant colitis and/or toxic megacolon * uc limited to rectum only or to less than (\<) 15 centimeters (cm) of colon * presence of a stoma * presence or history of fistula * history of extensive colonic resection (example, \<30 cm of colon remaining) * diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, crohn's colitis or clinical findings suggestive of crohn's disease